On March 19, 2026, Genelux Corporation announced that it has entered into a Sales Agreement with TD Securities (USA) LLC, allowing the company to offer and sell shares of its common stock valued at up to $100 million. This agreement enables Genelux to raise capital through the sale of Placement Shares, which will be conducted at market prices. The shares will be sold under the company's existing Registration Statement on Form S-3, which was declared effective by the SEC in February 2024. The proceeds from this offering are intended for general corporate purposes, including research and development, clinical trials, and working capital. TD Securities will act as the sales agent and will receive a commission of up to 3% on the gross proceeds from the sales. The company retains the right to suspend sales at any time, providing flexibility in managing its capital needs. This strategic move is expected to enhance Genelux's liquidity position, allowing it to fund its ongoing projects and operational expenses effectively. The company has indicated that it is not obligated to sell any shares under this agreement, which provides a safety net in case market conditions are not favorable. Overall, this agreement is seen as a positive step for Genelux, as it positions the company to capitalize on market opportunities while maintaining control over its capital structure.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.